drugset / Trial / NCT04466345

Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder

NCT04466345

Phase 2 Completed 72 enrolled University Health Network, Toronto
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will examine whether semaglutide may improve cognitive function in individuals with major depressive disorder (MDD).

Timeline

Start
2021-10-06
Primary completion
2024-12-27
Completion
2024-12-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Semaglutide Peptide 14 mg Oral